NL-OMON48625RecruitingNot Applicable
Comparative analysis of KRAS and EGFR mutation detection in liquid biopsy vs tissue biopsy in patients with NSCLC - COMMUNIST
Jeroen Bosch Ziekenhuis0 sites150 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Patients with NSCLC (initial diagnosis and progressive disease) that are eligible for KRAS/EGFR mutation analysis on tissue biopsy as performed for standard of care.
Exclusion Criteria
- •Patients with NSCLC where tissue biopsy was not successful.
Investigators
Similar Trials
Completed
Not Applicable
Effects of mutations in KRAS and BRAF gene and histological parameters on the clinical course of disease in patients with metastatic colorectal cancerMetastatic colorectal cancerMalignant neoplasm of colonCancerISRCTN10604174Institute of Oncology Ljubljana (Slovenia)400
Not yet recruiting
Not Applicable
The study for detecting EGFR and K-ras mutation in plasma of patinets with cancercancerJPRN-UMIN000012460Department of Clinical Oncology, Osaka Medical Center for Cancer and Cardiovascular diseases100
Completed
Phase 2
Detection of EGFR and K-ras gene mutations in serum of non-small cell lung cancer patientsAdenocarcinoma of the lungJPRN-UMIN000006762Osaka Medical Center for Cancer and Cardiovascular Diseases288
Completed
Not Applicable
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer PatientsLung NeoplasmsKRAS Gene MutationEGFR Gene MutationNCT03171636Hospital Erasto Gaertner130
Completed
Not Applicable
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRIColorectal CancerNCT03698253Kaohsiung Medical University Chung-Ho Memorial Hospital41